News CANbridge Pharmaceuticals Inc.

Equities

1228

KYG1821D1097

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 am EDT			5-day change	1st Jan Change
0.34 ^HKD	-1.45%		-1.45%	-65.66%

Apr. 23	Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials	MT
Apr. 22	CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials	Apr. 22	MT
CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme	Apr. 22	CI
CANbridge Pharmaceuticals Inc. Announces Change of Principal Place of Business in Hong Kong, Effect from April 15, 2024	Apr. 12	CI
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
CANbridge and PUMCH announced the establishment of PUMCH, CANbridge Genetic Defect Rare Disease Innovation and Translation Base	Mar. 04	AQ
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares	Feb. 07	MT
CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee	Nov. 23	CI
CANbridge Pharmaceuticals - Foundation consolidated over time and for a rosy future, 2023 China Conference on Rare Diseases closed successfully	Nov. 07	AQ
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress	23-10-26	AQ
CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress	23-10-25	CI
CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration	23-10-18	AQ
CANbridge Announces NDA Acceptance of CAN108 (®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration	23-10-16	CI
CANbridge Announces Full Enrollment Reached in the Core Part of the CAN103 Phase 2 trial for Gaucher Disease in China	23-10-16	AQ
Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China	23-10-16	CI
CANbridge Announces Marketing Approval of CAN108 in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	23-10-09	AQ
Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	23-10-08	CI
CANbridge to Participate in Two Investor Conferences in September	23-09-07	AQ
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows	23-08-31	MT
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Transcript : CANbridge Pharmaceuticals Inc. - Special Call	23-06-27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News CANbridge Pharmaceuticals Inc.

Equities

1228

KYG1821D1097

Summary

Filters